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40 Poster Session-Ipredicators of OS: age, gender, diagnosis, KPS, stem cell source,
LVEF, resting HR and O2sat, reaching target HR, DLCOcorr
and FEV1. For allogeneic BMT, multivariate analysis demon-
strated age\40 years (RR 5 0.37, p 5 0.03) and higher FEV1
(RR 5 0.98, p 5 0.02) had a decreased risk and KPS#80 (RR
5 3.19, p 5 0.01) had increased risk of death. For autologous
BMT, multivariate analysis demonstrated significantly decreased
risk of death for higher baseline HR (RR 5 0.95, p 5 0.002),
baseline O2sat (RR 5 0.69, p 5 0.01), LVEF (RR 5 0.91, p
5 0.04) and DLCOcorr (RR 5 0.97, p 5 0.02). Early OS
may be predicted using simple measures of cardiac, pulmonary
and exercise functions pre-BMT.98
PRE-TRANSPLANT CLONAL CYTOGENETIC ABNORMALITIES IN STEM
CELLS USED FOR AUTOLOGOUS STEM CELL TRANSPLANT FOR RELAPSED
NON-HODGKIN LYMPHOMA IS A PREDICTOR OF RELAPSE
Rojas, A.M., De Vos, S., Pinter-Brown, L., Paquette, R., Schiller, S.,
Territo, M.C. UCLA, Los Angeles, CA
Autologous stem cell transplant is used for chemotherapy sensitive
relapsed Non-Hodgkin Lymphoma (NHL). Patients who receive an
autologous stem cell transplant after high dose chemotherapy for re-
lapsed NHL have significantly superior survival compared to those
receiving conventional chemotherapy. Relapsed patients who
achieve a second remission are treated with myeloablative chemo-
therapy followed by autologous stem cell transplant. These patients
can achieve 5-year event free survival close to 50% and 5-year overall
survival of greater than 50%. We performed a retrospective analysis
of our center’s transplant data and reviewed pre-transplant cytoge-
netic analysis on the patient’s collected stem cells. 259 patients un-
derwent autologous stem cell transplant from 1998 through 2007
for relapsed NHL. Cytogenetic evaluations of the patient’s pre-
transplant stem cells had been done to look for evidence of MDS
or characteristics of their lymphoma. Clonal cytogenetic abnormal-
ities were found in 12 of the 259 patients. Two of these patients died
within 45 days of transplant without evidence of relapse. One from
infection and a second from non-treatment related causes. Nine of
the remaining 11 (81%) patients with clonal cytogenetic abnormal-
ities have relapsed and died. All patients relapsed with their original
lymphoma. The cytogenetic abnormalities were varied. Out of the 9
relapses, 3 had cytogenetic abnormalities in the stem cells that are as-
sociated with lymphoma, 2 that are associated with AML, 1 that is
associated with MDS, and 2 were abnormalities whose significance
was unknown. In one patient cytogenetic changes of the original
lymphoma were identified. The patients that had clonal cytogenetic
abnormalities in their collected stem cells had an 81% relapse rate as
opposed to 30% in the patients whose stem cells had a normal kar-
yotype. Our findings show that cytogenetic changes in the collected
stem cells are associated with a higher rate of lymphoma relapse.99
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) WITH A PCR-NEG-
ATIVE GRAFT WAS ASSOCIATED WITH A FAVORABLE OUTCOME FOR
CORE-BINDING-FACTOR ACUTE MYELOID LEUKEMIA (CBF-AML)
Nakasone, H.1,2, Izutsu, K.1, Wakita, S.3, Yamaguchi, H.3, Muramatsu-
Kida, M.1, Usuki, K.1 1Kanto Medical Center NTT EC, Shinagawa-ku,
Tokyo, Japan; 2SaitamaMedical Center, Jichi Medical University, Grad-
uate School; 3Nippon Medical School
Although core binding factor acute myeloid leukemia (CBF-
AML) is generally considered to be a low-risk form of AML, the sur-
vival rate is still 50–60%. To evaluate the effectiveness of autologous
stem cell transplantation (ASCT) with a PCR-negative graft, we an-
alyzed a series of consecutive CBF-AML patients. Between 1997 and
2006, 18 patients aged less than 60 years were referred under a diag-
nosis of CBF-AML. Peripheral blood stem cells (PBSC) were col-
lected after a second or further course of post-remission therapy.
When more than 2.0 106/kg CD34-positive cells with minimal re-
sidual disease (MRD) undetectable by nested PCR had been col-
lected, ASCT was performed with busulfan, etoposide and
cytarabine combined with granulocyte colony-stimulating factor.
Event-free survival (EFS) and complications of ASCT were then as-sessed. Fourteen of the 18 patients received ASCT. The median ob-
servation period was 4.4 years. The 5-year EFS was 93% for ASCT
patients, despite the presence of adverse factors. In 8 of 10 patients
who had detectable MRD in the bone marrow before ASCT,
MRD became undetectable after ASCT. Neutrophils recovered
promptly within 2 weeks, but platelets recovered relatively slowly.
Half of the patients suffered from varicella zoster virus infection. Al-
though one case of myelodysplastic syndrome occurred, there was no
case of relapse. ASCTwith a PCR-negative graft was associated with
excellent EFS. For patients with CBF-AML, especially with adverse
factors or remnant MRD in the bone marrow, this strategy is the
treatment of choice.100
FEBRILE REACTIONS OCCURRING WITH SECOND CYCLE OF HIGH DOSE
MELPHALAN AND STEM CELL TRANSPLANTATION IN PATIENTS WITH
AL AMYLOIDOSIS: A ‘‘MELPHALAN RECALL’’ REACTION
Rosenzweig, M.A.1, Seldin, D.C.1, Remick, D.3, Skinner, M.2,
Quillen, K.1, Oran, B.2, Finn, K.T.1, Sanchorawala, V.1 1Boston Univer-
sityMedical Center, Boston,MA; 2Boston University Medical Center, Bos-
ton, MA; 3Boston University Medical Center, Boston, MA
Systemic AL amyloidosis is a clonal plasma cell disease character-
ized by the wide spread deposition of amyloid fibrils into tissues and
organs. Treatment for this disease is directed towards reducing the
production of amyloidogenic monoclonal light chains by attacking
the underlying plasma cell dyscrasia. Aggressive treatment with
high dose intravenous melphalan followed by autologous stem cell
transplantation (HDM/SCT) is effective in inducing hematologic
and clinical remissions and in extending survival. Tandem cycles of
HDM/SCT have been shown to increase hematologic complete re-
sponse (HCR) rates in patients with AL amyloidosis. Between April
1994 and July 2008, 57 patients with AL amyloidosis at Boston Uni-
versity medical center were treated with a second cycle of HDM/
SCT after failing to achieve a HCR following a first transplantation.
Eleven of 57 patients (19%) treated with tandem transplantation de-
veloped a high fever 12–24 hours following melphalan administra-
tion. Other clinical features noted in some of the patients include
hypotension, acute renal failure, and skin rash. Among the 11
patients described, there were 7 men and 4 women. The average
age was 53.5 years (range 41–60). The average peak temperature of
the 11 patients was 39.1oC (range, 38.1–39.4oC). All patients
experienced resolution of fever within 24–48 hours. Six of the 11 pa-
tients developed a rash and 5 developed hypotension that was re-
sponsive to intravenous fluids or pressors when indicated. Two of
the patients developed acute renal failure that improved following
resolution of the fever. In all 11 patients, workup for an infectious
etiology of fever was negative. One of the 11 patients described,
had cytokine measurements before, during and after the febrile
reaction. The concentration of several pro-inflammatory as well as
anti-inflammatory cytokines increased significantly. IL-6, a classic
endogenous, pyrogenic cytokine, increased 10 fold with this reaction
demonstrating a clear physiologic response correlating with the clin-
ical findings. We conclude that an unusual febrile reaction mediated
by pyrogenic cytokines can occur in patients with AL amyloidosis ex-
posed to a second cycle of high dose melphalan. While this reaction
has not been observed in patients with multiple myeloma treated in
similar fashion, clinicians should be aware of this phenomenon we
have termed a ‘‘melphalan recall’’ reaction in patients with AL amy-
loidosis treated with tandem cycles of HDM/SCT.101
CLINICAL PATHWAYS AND STANDARD OPERATING PROCEDURES: ES-
SENTIAL TOOLS FOR OUTPATIENT STEM CELL TRANSPLANT PROGRAMS
TREATING PATIENTS WITH AL AMYLOIDOSIS
Finn, K.T., Fennessey, S., Yanarella, L., Antonelli, C., Shelton, A.,
Daniel, S., Skinner, M., Seldin, D., Quillen, K., Sanchorawala, V. Boston
University Medical Center, Boston, MA
Clinical pathways (CPs) and standard operating procedures
(SOPs) are necessary for treating AL patients with high-dose mel-
phalan and stem cell transplantation (HDM/SCT) in the outpatient
setting. AL is a plasma cell dyscrasia in which abnormal proteins
